🚨 New trial: KEYNOTE-B15/EV-304 ➡️ perioperative MIBC EV + pembro vs cisplatin-gem 👉 2y EFS 79.4% vs 66.2% (HR 0.53) 👉 2y OS 86.9% vs 81.3% (HR 0.65) 👉 pCR 55.8% vs 32.5% ✅ Platinum-free and beats neoadjuvant cisplatin → new SOC, FDA approved Jul 20…
RP @nejm.org: Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEY…
RP @nejm.org: Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEY…
RP @nejm.org: Among cisplatin-eligible patients with muscle-invasive bladder cancer undergoing cystectomy, perioperative enfortumab vedotin–pembrolizumab led to significantly better event-free survival outcomes than cisplatin–gemcitabine. Full phase 3 KEY…